<DOC>
	<DOCNO>NCT01070069</DOCNO>
	<brief_summary>To determine safety effectiveness PEVAR .</brief_summary>
	<brief_title>Percutaneous Endovascular Aneurysm Repair ( PEVAR ) Trial</brief_title>
	<detailed_description>In &gt; 30 single center publication , percutaneous EVAR facilitate Prostar XL ProGlide closure demonstrate feasible . To date , multicenter , randomize control trial approach available . Moreover , although IntuiTrak System closure device commercially available US FDA-approved device , EVAR device closure device FDA approve totally percutaneous EVAR application . The IntuiTrak System indicate treatment abdominal aortic aneurysm aortic neck range size 18mm 32mm . The System include 19Fr integrated introducer sheath , design reduce exchange , may particularly important percutaneous approach . Moreover , device currently approve EVAR device contralateral percutaneous ( 9Fr ) indication . Patients abdominal aortic aneurysm suitable candidate endovascular repair use IntuiTrak System meet prospectively define inclusion/exclusion criterion specific trial randomize PEVAR standard EVAR use vascular exposure access ratio 2:1 . Physicians establish expert field percutaneous EVAR participate trial .</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Abdominal</mesh_term>
	<criteria>Male female least 18 year old Informed consent form understood sign patient agrees followup visit Abdominal aortic aneurysm ( AAA ) maximum diameter ≥5cm , range 4 5cm increase 0.5cm past six month Have suitable ipsilateral common femoral artery percutaneous access use 'Preclose ' technique detail protocol Anatomically eligible IntuiTrak System per FDAapproved indication use ( IFU ) Life expectancy &lt; 1 year judge investigator ; Psychiatric condition may interfere study ; Participating enrollment 30day followup phase another clinical study ; Known allergy device component ; Coagulopathy uncontrolled bleed disorder ; Ruptured , leaking , mycotic aneurysm ; Serum creatinine ( SCr ) level &gt; 1.7 mg/dL ; Traumatic vascular injury ; Active systemic localize groin infection ; Connective tissue disease ( e.g. , Marfan 's Syndrome ) ; Renal transplant patient ; Recent ( within prior three month ) cerebrovascular accident myocardial infarction ; Planned major intervention surgery within 30 day follow EVAR procedure ; Requirement arterial conduit access site ; Morbidly obese ( BMI≥40 ) ; Calcification throughout CFA target area anterior wall circumferentially &gt; 50 % posterior wall ; Femoral artery aneurysm , arteriovenous fistula pseudoaneurysm ; Evidence prior common femoral artery surgery ( e.g. , groin incision ) ; Prior clipbased vascular closure device placement either arterial access site ; Collagenbased vascular closure device placement either arterial access site within prior 90 day ; Femoral artery needle puncture either arterial access site within prior 30 day ; Hematoma ipsilateral arterial access site Significant scar ipsilateral arterial access site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Percutaneous</keyword>
	<keyword>Preclose</keyword>
	<keyword>Endologix</keyword>
	<keyword>Abbott Vascular</keyword>
	<keyword>Endovascular</keyword>
	<keyword>PEVAR</keyword>
	<keyword>Stent graft</keyword>
	<keyword>Suture mediate closure device</keyword>
</DOC>